MimiVax and RoswellPark report phase 2b SURVIVE trial data showing significant SurVaxM survival benefit in glioblastoma patients aged 65 and under ....
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials ... .
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials ... .